Lack of effect of ustekinumab in treatment of allergic contact dermatitis
Research output: Contribution to journal › Journal article › Research › peer-review
Allergic contact dermatitis is a chronic inflammatory T cell mediated disease that can be recalcitrant to existing treatments. Ustekinumab is a monocloncal antibody blocking IL-12 and IL-23, shown to be effective and safe for patients with psoriasis. Despite both IL-12 and IL-23 involvement in contact allergy, the effect of Ustekinumab on allergic contact dermatitis has not been reported.
Original language | English |
---|---|
Journal | Contact Dermatitis |
Volume | 65 |
Issue number | 4 |
Pages (from-to) | 227-30 |
Number of pages | 4 |
ISSN | 0105-1873 |
DOIs | |
Publication status | Published - 1 Oct 2011 |
ID: 40179388